Antonio will lead Entheras clinical team as they advance the Company's lead candidate, Ent001, through proof-of-concept studies and into Phase I clinical trials for type 1 diabetes and inflammatory bowel disease. He will also support efforts to further expand Entheras pipeline, using proceeds from the recent Series A financing [https://www.entherapharmaceuticals.com/enthera-pharmaceuticals-extends-series-a-financing-raising-a-total-of-e35-million/] (raising 35 million) to open new programs.
Antonio brings 22 years of experience in the pharmaceutical industry, ranging from translational medicine to late-stage drug development and commercialization. He has successfully contributed to the clinical development strategy and registration of numerous small molecules and biologics across therapeutic areas such as gastroenterology, rheumatology, nephrology, transplantation and rare diseases, at both global and regional levels.
Antonio joins Enthera from Galapagos, where he was Translational Medicine Leader. He previously held senior management positions at several other life sciences companies, including roles as Global Program Clinical Head at Novartis, Medical Director,
In addition to his industry experience, Antonio is a Board-certified surgeon and author of several publications in the areas of transplantation, immunology and rheumatology in major peer-reviewed journals. His academic experience focused on the execution of kidney and liver transplantation, organ harvesting and sharing, liver transplantation for hepatocellular carcinoma, and implementation of immunosuppressive regimens.
- ENDS - Notes To Editors About Enthera Enthera Srl is a biotech company developing first-in-class biologics to transform the treatment paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way. The Company's primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD).
Enthera's pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in beta cell and stem cell apoptosis in pancreas and gut, respectively.
The Company is building a pipeline of inhibitory monoclonal antibodies (mAbs) and fusion proteins targeting the pathway via multiple angles. Its lead program Ent001 is the only drug in development with the potential to restore the endogenous pancreatic stem cell compartment in T1D as well as the original intestine structure in IBD, in order to re-stablish organ function.
Enthera is a private company headquartered in
For more information, visit [https://www.entherapharmaceuticals.com/] Connect with us on LinkedIn [https://www.linkedin.com/company/enthera-pharmaceuticals/].
Issued for and on behalf of Enthera by
For more information please contact:
Enthera Pharmaceuticals
.
(C) 2021 M2 COMMUNICATIONS, source